Phibro Animal Health (NASDAQ:PAHC) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Saturday.

PAHC has been the topic of a number of other research reports. Credit Suisse Group upped their target price on Phibro Animal Health from $36.00 to $37.00 and gave the company an “outperform” rating in a research note on Thursday, August 31st. Zacks Investment Research cut Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. ValuEngine cut Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Piper Jaffray Companies set a $41.00 target price on Phibro Animal Health and gave the company a “buy” rating in a research note on Friday, October 6th. Finally, Bank of America reaffirmed an “underperform” rating and set a $33.00 target price on shares of Phibro Animal Health in a research note on Wednesday, August 23rd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $38.25.

Phibro Animal Health (NASDAQ:PAHC) opened at $33.75 on Friday. The company has a market capitalization of $1,356.18, a P/E ratio of 22.06, a PEG ratio of 3.96 and a beta of 1.28. Phibro Animal Health has a 52 week low of $26.10 and a 52 week high of $40.25. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.85 and a current ratio of 3.26.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Monday, November 6th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.01. The firm had revenue of $193.40 million for the quarter, compared to analysts’ expectations of $189.89 million. Phibro Animal Health had a return on equity of 42.75% and a net margin of 8.87%. The company’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.36 earnings per share. sell-side analysts forecast that Phibro Animal Health will post 1.57 EPS for the current year.

In related news, CFO Richard G. Johnson sold 29,807 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $35.66, for a total value of $1,062,917.62. Following the transaction, the chief financial officer now owns 4,240 shares of the company’s stock, valued at $151,198.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Larry Lee Miller sold 32,459 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $35.59, for a total value of $1,155,215.81. Following the completion of the transaction, the chief operating officer now directly owns 4,237 shares in the company, valued at approximately $150,794.83. The disclosure for this sale can be found here. In the last three months, insiders sold 279,791 shares of company stock worth $10,118,331. 51.88% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in PAHC. Vanguard Group Inc. grew its stake in Phibro Animal Health by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,729,406 shares of the company’s stock worth $48,597,000 after purchasing an additional 130,935 shares in the last quarter. Geode Capital Management LLC boosted its position in Phibro Animal Health by 9.9% during the 1st quarter. Geode Capital Management LLC now owns 162,869 shares of the company’s stock valued at $4,576,000 after acquiring an additional 14,655 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Phibro Animal Health by 12.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 396,007 shares of the company’s stock valued at $11,128,000 after acquiring an additional 43,260 shares in the last quarter. Morgan Stanley boosted its position in Phibro Animal Health by 1.7% during the 1st quarter. Morgan Stanley now owns 172,773 shares of the company’s stock valued at $4,855,000 after acquiring an additional 2,868 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Phibro Animal Health by 269.8% during the 1st quarter. Renaissance Technologies LLC now owns 51,400 shares of the company’s stock valued at $1,444,000 after acquiring an additional 37,500 shares in the last quarter. 48.42% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Phibro Animal Health (PAHC) Rating Lowered to Sell at BidaskClub” was published by Daily Political and is owned by of Daily Political. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/12/04/phibro-animal-health-pahc-rating-lowered-to-sell-at-bidaskclub.html.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Receive News & Ratings for Phibro Animal Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.